Antibiotic exposure in neonates and early adverse outcomes: A systematic review and meta-analysis

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 7, 2017, Pages 1858-1870

  Esaiassen, Eirin ^a,b   Fjalstad, Jon Widding ^a,b   Juvet, Lene Kristine ^c,d   van den Anker, John N ^e,f   Klingenberg, Claus ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^d UNIVERSITY OF SOUTH EASTERN NORWAY   (Norway)

^e UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^f CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEFOTAXIME; CEPHALOSPORIN DERIVATIVE; GENTAMICIN; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT;

ADVERSE OUTCOME; ARTICLE; DRUG FATALITY; HUMAN; META ANALYSIS; MORTALITY; NECROTIZING ENTEROCOLITIS; OBSERVATIONAL STUDY; PERINATAL DRUG EXPOSURE; PREMATURITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW; SYSTEMIC MYCOSIS; TREATMENT DURATION; INFANT; INFANT MORTALITY; NEWBORN; RISK FACTOR; SEPSIS;

ANTI-BACTERIAL AGENTS; ENTEROCOLITIS, NECROTIZING; HUMANS; INFANT; INFANT MORTALITY; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; INVASIVE FUNGAL INFECTIONS; OBSERVATIONAL STUDIES AS TOPIC; RISK FACTORS; SEPSIS;

EID: 85042683861     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx088     Document Type: Article

References (78)

1. Bizzarro MJ, Raskind C, Baltimore RS, et al. Seventy-five years of neonatal sepsis at Yale: 1928-2003. Pediatrics 2005; 116: 595-602.
2. Stoll BJ, Gordon T, Korones SB, et al. Late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr 1996; 129: 63-71.
3. Stoll BJ,HansenNI, Bell EF, et al. Trends in care practices, morbidity, andmortality of extremely preterm neonates, 1993-2012. JAMA 2015; 314: 1039-51.
4. Fjalstad JW, Stensvold HJ, Bergseng H, et al. Early-onset sepsis and antibiotic exposure in term infants: a nationwide population-based study in Norway. Pediatr Infect Dis J 2016; 35: 1-6.
5. Hsieh EM, Hornik CP, Clark RH, et al.Medication use in the neonatal intensive care unit.AmJ Perinatol 2014; 31: 811-21.
6. Ronnestad A, Abrahamsen TG, Medbo S, et al. Septicemia in the first week of life in a Norwegian national cohort of extremely premature infants. Pediatrics 2005; 115: e262-8.
7. Ting JY, Synnes A, Roberts A, et al. Association between antibiotic use and neonatal mortality and morbidities in very low-birth-weight infants without culture-proven sepsis or necrotizing enterocolitis. JAMA Pediatr 2016; 170: 1181-7.
8. National Collaborating Centre forWomen's and Children's Health. National Institute for Health and Clinical Excellence (NICE) Guideline. Antibiotics for Early-onset Neonatal Infection: Antibiotics for the Prevention and Treatment of Early-onset Neonatal infection. 2012. https://www.nice.org.uk/guidance/ cg149.
9. Polin RA. Management of neonates with suspected or proven early-onset bacterial sepsis. Pediatrics 2012; 129: 1006-15.
10. Escobar GJ, Puopolo KM,Wi S, et al. Stratification of risk of early-onset sepsis in newborns ≥ 34 weeks' gestation. Pediatrics 2014; 133: 30-6.
11. de Man P, Verhoeven BA, Verbrugh HA, et al. An antibiotic policy to prevent emergence of resistant bacilli. Lancet 2000; 355: 973-8.
12. Bailey LC, Forrest CB, Zhang P, et al. Association of antibiotics in infancy with early childhood obesity. JAMA Pediatr 2014; 168: 1063-9.
13. Hoskin-Parr L, Teyhan A, Blocker A, et al. Antibiotic exposure in the first two years of life and development of asthma and other allergic diseases by 7.5 yr: a dose-dependent relationship. Pediatr Allergy Immunol 2013; 24: 762-71.
14. Kronman MP, Zaoutis TE, Haynes K, et al. Antibiotic exposure and IBD development among children: a population-based cohort study. Pediatrics 2012; 130: e794-803.
15. Higgins JPT, Altman DG, Sterne JAC, eds. Assessing risk of bias in included studies. In: LPT Higgins, S Green, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (Updated March 2011). The Cochrane Collaboration, 2011. http://www.handbook.cochrane.org/.
16. Loke YK, Price D, Herxheimer A. Systematic reviews of adverse effects: framework for a structured approach. BMCMed ResMethodol 2007; 7: 32.
17. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62: e1-34.
18. Klingenberg C, Fjalstad JW, Esaiassen E, et al. A Systematic Review of Early Adverse Effects Associated with Antibiotic Exposure in the Neonatal Period. http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID"CRD 42015026743.
19. Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin NorthAm1986; 33: 179-201.
20. Viswanathan M, Berkman ND, Dryden DM, et al. (Eds). AHRQMethods for Effective Health Care. In: Assessing Risk of Bias and Confounding in Observational Studies of Interventions or Exposures: Further Development of the RTI Item Bank. Methods Research Report. Rockville, MD: Agency for Healthcare Research and Quality (US), 2013. https://www.effectivehealth care.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=display product&productid=1612.
21. Harms K, Herting E, KronMet al. Randomized, controlled trial of amoxicillin prophylaxis for prevention of catheter-related infections in newborn infants with central venous silicone elastomer catheters. J Pediatr 1995; 127: 615-9.
22. Auriti C, Ravá L, Ciommo V, et al. Short antibiotic prophylaxis for bacterial infections in a neonatal intensive care unit: a randomized controlled trial. JHosp Infect 2005; 59: 292-8.
23. Snelling S, Hart CA, Cooke RW. Ceftazidime or gentamicin plus benzylpenicillin in neonates less than forty-eight hours old. J Antimicrob Chemother 1983; 12 Suppl A: 353-6.
24. Tewari VV, Jain N. Monotherapy with amikacin or piperacillintazobactamempirically in neonates at risk for early-onset sepsis: a randomized controlled trial. J TropPediatr 2014; 60: 297-302.
25. Tagare A, Kadam S, Vaidya U, et al. Routine antibiotic use in preterm neonates: a randomised controlled trial.JHosp Infect 2010; 74: 332-6.
26. De Louvois J, Dagan R, Tessin I. A comparison of ceftazidime and aminoglycoside based regimens as empirical treatment in 1316 cases of suspected sepsis in the newborn. Eur J Pediatr 1992; 151: 876-84.
27. Metsvaht T, Ilmoja ML, Parm U, et al. Comparison of ampicillin plus gentamicin vs. penicillin plus gentamicin in empiric treatment of neonates at risk of early onset sepsis. Acta Paediatr 2010; 99: 665-72.
28. Millar MR, MacKay P, Levene M, et al. Enterobacteriaceae and neonatal necrotising enterocolitis. Arch Dis Child 1992; 67: 53-6.
29. Hall MA, Ducker DA, Lowes JA, et al. A randomised prospective comparison of cefotaxime versus netilmicin/penicillin for treatment of suspected neonatal sepsis. Drugs 1988; 35 Suppl 2: 169-77.
30. Kuppala VS, Meinzen-Derr J, Morrow AL, et al. Prolonged initial empirical antibiotic treatment is associated with adverse outcomes in premature infants. J Pediatr 2011; 159: 720-5.
31. Cordero L, Ayers LW. Duration of empiric antibiotics for suspected earlyonset sepsis in extremely low birth weight infants. Infect Control Hosp Epidemiol 2003; 24: 662-6.
32. Cotten CM, McDonald S, Stoll B, et al. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics 2006; 118: 717-22.
33. Cotten CM, Taylor S, Stoll B, et al. Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. Pediatrics 2009; 123: 58-66.
34. Abdel Ghany EA, Ali AA. Empirical antibiotic treatment and the risk of necrotizing enterocolitis and death in very low birth weight neonates. Ann SaudiMed 2012; 32: 521-6.
35. Shah P, Nathan E, Doherty D, et al. Prolonged exposure to antibiotics and its associations in extremely preterm neonates - the Western Australian experience. JMatern Fetal Neonatal Med 2013; 26: 1710-4.
36. Chong E, Reynolds J, Shaw J, et al. Results of a two-center, before and after study of piperacillin-tazobactam versus ampicillin and gentamicin as empiric therapy for suspected sepsis at birth in neonates ≤ 1500 g. J Perinatol 2013; 33: 529-32.
37. Clark RH, Bloom BT, Spitzer AR, et al. Empiric use of ampicillin and cefotaxime, compared with ampicillin and gentamicin, for neonates at risk for sepsis is associated with an increased risk of neonatal death. Pediatrics 2006; 117: 67-74.
38. FejaKN,Wu F, RobertsKet al. Risk factors for candidemia in critically ill infants: amatched case-control study. J Pediatr 2005; 147: 156-61.
39. Singh K, Chakrabarti A, Narang A, et al. Yeast colonisation & fungaemia in preterm neonates in a tertiary care centre. Indian J Med Res 1999; 110: 169-73.
40. Ariff S, Saleem AF, Soofi SB, et al. Clinical spectrum and outcomes of neonatal candidiasis in a tertiary care hospital in Karachi, Pakistan. J Infect Dev Ctries 2011; 5: 216-23.
41. Faix RG, Kovarik SM, Shaw TR, et al.Mucocutaneous and invasive candidiasis among very low birth weight (less than 1,500 grams) infants in intensive care nurseries: a prospective study. Pediatrics 1989; 83: 101-7.
42. Manzoni P, FarinaD, LeonessaMet al. Risk factors for progression to invasive fungal infection in preterm neonates with fungal colonization. Pediatrics 2006; 118: 2359-64.
43. Pera A, Byun A, Gribar S, et al. Dexamethasone therapy and Candida sepsis in neonates less than 1250 grams. J Perinatol 2002; 22: 204-8.
44. Saiman L, Ludington E, Pfaller M, et al. Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J 2000; 19: 319-24.
45. Warris A, Semmekrot BA, Voss A. Candidal and bacterial bloodstream infections in premature neonates: a case-control study. Med Mycol 2001; 39: 75-9.
46. Weese-Mayer DE, Fondriest DW, Brouillette RT, et al. Risk factors associated with candidemia in the neonatal intensive care unit: a case-control study. Pediatr Infect Dis J 1987; 6: 190-6.
47. Yu Y, Du L, Yuan T, et al. Risk factors and clinical analysis for invasive fungal infection in neonatal intensive care unit patients. Am J Perinatol 2013; 30: 589-94.
48. Benjamin DK Jr, DeLong ER, SteinbachWJ, et al. Empirical therapy for neonatal candidemia in very low birth weight infants. Pediatrics 2003; 112: 543-7.
49. Benjamin DK Jr, Stoll BJ, Fanaroff AA, et al. Neonatal candidiasis among extremely low birthweight infants: risk factors,mortality rates, and neurodevelopmental outcomes at 18 to 22months. Pediatrics 2006; 117: 84-92.
50. Lee JH, Hornik CP, Benjamin DK Jr, et al. Risk factors for invasive candidiasis in infants.1500 g birth weight. Pediatr Infect Dis J 2013; 32: 222-6.
51. Linder N, Levit O, Klinger G, et al. Risk factors associated with candidaemia in the neonatal intensive care unit: a case-control study. J Hosp Infect 2004; 57: 321-4.
52. Krediet TG, van Lelyveld N, Vijlbrief DC, et al.Microbiological factors associated with neonatal necrotizing enterocolitis: protective effect of early antibiotic treatment. Acta Paediatr 2003; 92: 1180-2.
53. Mufti P, Bhutta ZA. Necrotizing enterocolitis in infants weighing less than 2000G. J PakMedAssoc 1992; 42: 37-9.
54. Stoll BJ, Kanto WP Jr, Glass RI, et al. Epidemiology of necrotizing enterocolitis: a case control study. J Pediatr 1980; 96: 447-51.
55. Wang Y, Hoenig JD, Malin KJ, et al. 16S rRNA gene-based analysis of fecal microbiota from preterm infants with and without necrotizing enterocolitis. ISME J 2009; 3: 944-54.
56. Alexander VN, Northrup V, Bizzarro MJ. Antibiotic exposure in the newborn intensive care unit and the risk of necrotizing enterocolitis. J Pediatr 2011; 159: 392-7.
57. Greenwood C, Morrow AL, Lagomarcino AJ, et al. Early empiric antibiotic use in preterm infants is associated with lower bacterial diversity and higher relative abundance of Enterobacter. J Pediatr 2014; 165: 23-9.
58. Allen TR, Da SilvaOP. Choice of antibiotics in late neonatal sepsis in the extremely low birthweight infant. Can J Infect Dis 2003; 14: 28-31.
59. Lin CH, Wang LW, Wang ST, et al. Duration of endotracheal intubation and candidemia in very low-birth-weight infants. Clin Neonatol 1998; 5: 1-5.
60. Benjamin DK Jr, Ross K, McKinney RE Jr, et al.When to suspect fungal infection in neonates: a clinical comparison of Candida albicans and Candida parapsilosis fungemia with coagulase-negative staphylococcal bacteremia. Pediatrics 2000; 106: 712-8.
61. Benjamin DK Jr, Stoll BJ, Gantz MG, et al. Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. Pediatrics 2010; 126: e865-73.
62. Chang YJ, Choi IR, ShinWS, et al. The control of invasive Candida infection in very low birth weight infants by reduction in the use of 3rd generation cephalosporin. Korean J Pediatr 2013; 56: 68-74.
63. Aliaga S, Clark RH, LaughonM, et al. Changes in the incidence of candidiasis in neonatal intensive care units. Pediatrics 2014; 133: 236-42.
64. Fu J, Wang X, Wei B, et al. Risk factors and clinical analysis of candidemia in very-low-birth-weight neonates. AmJ Infect Control 2016; 44: 1321-5.
65. Cantey JB,Wozniak PS, Pruszynski JE, et al. Reducing unnecessary antibiotic use in the neonatal intensive care unit (SCOUT): a prospective interrupted time-series study. Lancet Infect Dis 2016; 16: 1178-84.
66. La Rosa PS, Warner BB, Zhou Y, et al. Patterned progression of bacterial populations in the premature infant gut. Proc Natl Acad Sci USA 2014; 111: 12522-7.
67. Russell SL, Gold MJ, Hartmann M, et al. Early life antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma. EMBO Rep 2012; 13: 440-7.
68. Grishin A, Bowling J, Bell B, et al. Roles of nitric oxide and intestinal microbiota in the pathogenesis of necrotizing enterocolitis. J Pediatr Surg 2016; 51: 13-7.
69. Baumler AJ, Sperandio V. Interactions between the microbiota and pathogenic bacteria in the gut. Nature 2016; 535: 85-93.
70. Dardas M, Gill SR, Grier A, et al. The impact of postnatal antibiotics on the preterm intestinalmicrobiome. Pediatr Res 2014; 76: 150-8.
71. Deshmukh HS, Liu Y, Menkiti OR, et al. The microbiota regulates neutrophil homeostasis and host resistance to Escherichia coli K1 sepsis in neonatal mice. NatMed 2014; 20: 524-30.
72. Waggoner-Fountain LA,Walker MW, Hollis RJ, et al. Vertical and horizontal transmission of unique Candida species to premature newborns. Clin Infect Dis 1996; 22: 803-8.
73. Leibovitz E, Livshiz-Riven I, Borer A, et al. A prospective study of the patterns and dynamics of colonization with Candida spp. in very low birth weight neonates. Scand J Infect Dis 2013; 45: 842-8.
74. Mason KL, Erb Downward JR, Mason KD, et al. Candida albicans and bacterial microbiota interactions in the cecum during recolonization following broad-spectrum antibiotic therapy. Infect Immun 2012; 80: 3371-80.
75. Rosenbach A, Dignard D, Pierce JV, et al. Adaptations of Candida albicans for growth in themammalian intestinal tract. Eukaryot Cell 2010; 9: 1075-86.
76. Baley JE, Kliegman RM, Boxerbaum B, et al. Fungal colonization in the very low birth weight infant. Pediatrics 1986; 78: 225-32.
77. Pappu-Katikaneni LD, Rao KP, Banister E. Gastrointestinal colonization with yeast species and Candida septicemia in very low birth weight infants. Mycoses 1990; 33: 20-3.
78. Cotten CM. Adverse consequences of neonatal antibiotic exposure. Curr Opin Pediatr 2016; 28: 141-9.